Advanced search
Publication Cover
Future Oncology Volume 5, 2009 - Issue 7
Submit an article Journal homepage
187
Views
0
CrossRef citations to date
0
Altmetric
Review

Clinical States Model for Biomarkers in Bladder Cancer

Andrea B ApoloGenitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY10021, USA; and, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA. [email protected]View further author information
,
Matthew MilowskyGenitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY10021, USA; and, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA. [email protected]View further author information
&
Dean F BajorinGenitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY10021, USA; and, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA. [email protected]Correspondence[email protected]
View further author information
Pages 977-992 | Published online: 30 Sep 2009

Bibliography

  • Whelan P : Bladder cancer – contemporary dilemmas in its management.Eur. Urol.53(1), 24–26 (2008).
  • Botteman MF , PashosCL, RedaelliA, LaskinB, HauserR: The health economics of bladder cancer: a comprehensive review of the published literature.Pharmacoeconomics21(18), 1315–1330 (2003).
  • Stein JP , LieskovskyG, CoteRet al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients.J. Clin. Oncol.19(3), 666–675 (2001).
  • von der Maase H , SengelovL, RobertsJTet al.: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.J. Clin. Oncol.23(21), 4602–4608 (2005).
  • Bishop J , WeinbergRA: Molecular Oncology. Scientific American, Inc., New York, NY, USA (1996).
  • Osman I , BajorinDF, SunT-Tet al.: Novel blood biomarkers of human urinary bladder cancer.Clin. Cancer Res.12(11), 3374–3380 (2006).
  • Apolo AB , OsmanI, ShenR, OlshenAB, BajorinDF: Peripheral-blood gene expression profiling in bladder cancer (BC) patients (pts).Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 5076).
  • Nagrath S , SequistLV, MaheswaranSet al.: Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature450(7173), 1235–1239 (2007).
  • Scher HI , HellerG: Clinical states in prostate cancer: towards a dynamic model of disease progression.Urology55, 323–327 (2000).
  • Pagano F , BassiP, GalettiTPet al.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification.J. Urol.145(1), 45–50 (1991).
  • Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 7(361), 1927–1934 (2003).
  • Grossman HB , NataleRB, TangenCMet al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N. Engl. J. Med.349, 859–866 (2003).
  • Hall RR on behalf of the Intl Collaboration of Trialists of the MRC Advanced Bladder Cancer Group MCTU, London, UK: Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc. Am. Soc. Clin. Oncol. 21, 178a (2002) (Abstract 710).
  • Advanced Bladder Cancer (ABC) Meta-analysis Collaboration : Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.Eur. Urol.48(2), 202–206 (2005).
  • Splinter TA , ScherHI, DenisLet al.: The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer – Genitourinary Group.J. Urol.147, 606–608 (1992).
  • Schultz PK , HerrHW, ZhangZFet al.: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.J. Clin. Oncol.12(7), 1394–1401 (1994).
  • Herr HW : Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.Eur. Urol.54(1), 126–132 (2008).
  • von der Maase H , HansenSW, RobertsJTet al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized multicenter, multinational multicenter, Phase III study.J. Clin. Oncol.18, 3068–3077 (2000).
  • Marrer E , DieterleF: Biomarkers in oncology drug development: rescuers or troublemakers?Expert Opin. Drug Metab. Toxicol.4(11), 1391–1402 (2008).
  • Messing EM , MadebR, YoungTet al.: Long-term outcome of hematuria home screening for bladder cancer in men.Cancer107(9), 2173–2179 (2006).
  • Hemstreet GP 3rd , YinS, MaZet al.: Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine.J. Natl Cancer Inst.93(6), 427–436 (2001).
  • Lotan Y , SvatekRS, SagalowskyAI: Should we screen for bladder cancer in a high-risk population?Cancer107(5), 982–990 (2006).
  • Black PC , BrownGA, DinneyCP: Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.J. Clin. Oncol.24(35), 5528–5535 (2006).
  • Lokeshwar VB , HabuchiT, GrossmanHBet al.: Bladder tumor markers beyond cytology: International Consensus Panel on Bladder Tumor Markers.Urology66(6 Suppl. 1), 35–63 (2005).
  • Lokeshwar VB , SolowayMS: Current bladder tumor tests: does their projected utility fulfill clinical necessity?J. Urol.165(4), 1067–1077 (2001).
  • Grossman HB , SolowayM, MessingEet al.: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.JAMA295(3), 299–305 (2006).
  • Kumar AKR , GuptaNP: Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.Jpn. J. Clin. Oncol.36(3), 172–175 (2006).
  • Stampfer DS , CarpinitoGA, Rodriguez-VillanuevaJet al.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.J. Urol.159(2), 394–398 (1998).
  • Wiener HG , MianC, HaitelA, PychaA, SchatzlG, MarbergerM: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?J. Urol.159(6), 1876–1880 (1998).
  • Sarosdy MF , HudsonMA, EllisWJet al.: Improved detection of recurrent bladder cancer using the bard BTA stat test.Urology50(3), 349–353 (1997).
  • Heicappell R , MullerM, FimmersR, MillerK: Qualitative determination of urinary human complement factor H-related protein (hcfHrp) in patients with bladder cancer, healthy controls, and patients with benign urologic disease.Urol. Int.65(4), 181–184 (2000).
  • Pode DSA , WaldM, NativO, LauferM, KaverI: Noninvasive detection of bladder cancer with the BTA Stat test.J. Urol.161(2), 443–446 (1999).
  • Ellis WJ , BlumensteinBA, IshakLM, EnfieldDL: Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumors.Urology50(6), 882–887 (1997).
  • Thomas L , LeyhH, MarbergerMet al.: Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.Clin. Chem.45(4), 472–477 (1999).
  • Alvarez A , LokeshwarVB: Bladder cancer biomarkers: current developments and future implementation.Curr. Opin. Urol.17(5), 341–346 (2007).
  • Salz W , EisenbergD, PlesciaJet al.: A survivin gene signature predicts aggressive tumor behavior.Cancer Res.65(9), 3531–3534 (2005).
  • Altieri DC : Validating survivin as a cancer therapeutic target.Nat. Rev. Cancer3(1), 46–54 (2003).
  • Smith SD , WheelerMA, PlesciaJ, ColbergJW, WeissRM, AltieriDC: Urine detection of survivin and diagnosis of bladder cancer.JAMA285(3), 324–328 (2001).
  • Weikert SCF , SchraderM, KrauseH, MillerK, MüllerM: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.Int. J. Cancer116(1), 100–104 (2005).
  • Pu XY , WangZP, ChenYR, WangXH, WuYL, WangHP: The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.J. Cancer Res. Clin. Oncol.134(6), 659–665 (2008).
  • Eissa S , Ali-LabibR, SwellamM, BassionyM, TashF, El-ZayatTM: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.Eur. Urol.52(5), 1388–1397 (2007).
  • Eissa S , SwellamM, LabibRA, El-ZayatT, El AhmadyO: A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot.J. Urol.181(3), 1353–1360 (2009).
  • Lodde M , MianC, NegriGet al.: Role of uCyt+ in the detection and surveillance of urothelial carcinoma.Urology61(1), 243–247 (2003).
  • Pfister C , ChautardD, DevonecMet al.: Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a french multicenter study.J. Urol.169(3), 921–924 (2003).
  • Hautmann S , TomaM, GomezMFLet al.: Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.Eur. Urol.46(4), 466–471 (2004).
  • Messing EM , TeotL, KormanHet al.: Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States.J. Urol.174(4 Part 1), 1238–1241 (2005).
  • Mian C , PychaA, WienerH, HaitelA, LoddeM, MarbergerM: Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract.J. Urol.161(5), 1486–1489 (1999).
  • Mian C , MaierK, ComplojEet al.: uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses.Cancer108(1), 60–65 (2006).
  • Lokeshwar VB , IidaN, BourguignonLYW: The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation.J. Biol. Chem.271(39), 23853–23864 (1996).
  • Eissa S , KassimSK, LabibRA, El-KhoulyIMet al.: Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.Cancer103(7), 1356–1362 (2005).
  • Yoder BJ , SkacelM, HedgepethRet al.: Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.Am. J. Clin. Pathol.127(2), 295–301 (2007).
  • Sarosdy MF , SchellhammerP, BokinskyGet al.: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.J. Urol.168(5), 1950–1954 (2002).
  • Friedrich MG , TomaAH, PantelK, WeisenbergerDJ, NoldusJ, HulandH: Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer.BJU Int.92(9), 911–914 (2003).
  • Laudadio J , KeaneTE, ReevesHMet al.: Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice.BJU Int.96(9), 1280–1285 (2005).
  • Zakian VA : Life and cancer without telomerase.Cell91(1), 1–3 (1997).
  • Sanchini MA , GunelliR, NanniOet al.: Relevance of urine telomerase in the diagnosis of bladder cancer.JAMA294(16), 2052–2056 (2005).
  • Liu BCS , LoughlinKR: Telomerase in human bladder cancer.Urol. Clin. North Am.27(1), 115–123 (2000).
  • Mao L , SchoenbergMP, ScicchitanoMet al.: Molecular detection of primary bladder cancer by microsatellite analysis.Science271(5249), 659–662 (1996).
  • Fearon ER , FeinbergAP, HamiltonSH, VogelsteinB: Loss of genes on the short arm of chromosome 11 in bladder cancer.Nature318(6044), 377–380 (1985).
  • Yoon DS , LiL, ZhangRDet al.: Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease.Oncogene20(36), 5005–5014 (2001).
  • Presti JC , ReuterVE, GalanT, FairWR, Cordon-CardoC: Molecular genetic alterations in superficial and locally advanced human bladder cancer.Cancer Res.51, 5405–5409 (1991).
  • Frigerio S , PadbergBC, StrebelRTet al.: Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis.Int. J. Cancer121(2), 329–338 (2007).
  • Rouprêt M , HupertanV, YatesDRet al.: A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.BJU Int.101(11), 1448–1453 (2008).
  • Knowles MA : Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.World J. Urol.25(6), 581–593 (2007).
  • Wu XR : Urothelial tumorigenesis: a tale of divergent pathways.Nat. Rev. Cancer5(9), 713–725 (2005).
  • Jebar AH , HurstCD, TomlinsonDC, JohnstonC, TaylorCF, KnowlesMA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.Oncogene24(33), 5218–5225 (2005).
  • Black PC , AgarwalPK, DinneyCP: Targeted therapies in bladder cancer – an update.Urol. Oncol.25(5), 433–438 (2007).
  • Tomlinson DC , BaldoO, HarndenP, KnowlesMA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.J. Pathol.213(1), 91–98 (2007).
  • van Rhijn BW , VisAN, van der KwastTHet al.: Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.J. Clin. Oncol.21(10), 1912–1921 (2003).
  • Hernandez S , Lopez-KnowlesE, LloretaJet al.: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.J. Clin. Oncol.24(22), 3664–3671 (2006).
  • van Rhijn BWG , LurkinI, RadvanyiF, KirkelsWJ, van der KwastTH, ZwarthoffEC: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.Cancer Res.61(4), 1265–1268 (2001).
  • Lindgren D , LiedbergF, AnderssonAet al.: Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.Oncogene25(18), 2685–2696 (2006).
  • Lopez-Knowles E , HernandezS, MalatsNet al.: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.Cancer Res.66(15), 7401–7404 (2006).
  • Hoque MO , BegumS, BraitMet al.: Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer.J. Urol.179(2), 743–747 (2008).
  • Ellinger J , El KassemN, HeukampLCet al.: Hypermethylation of cell-free serum dna indicates worse outcome in patients with bladder cancer.J. Urol.179(1), 346–352 (2008).
  • Vleminckx K , VakaetL, MareelM, FiersW, Van RoyF: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.Cell66(1), 107–119 (1991).
  • Durkan GC , BrotherickI, MellonJK: The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin.BJU Int.83(4), 424–428 (1999).
  • Shi B , LaudonV, YuS, DongD, ZhuY, XuZ: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.Urol. Int.81(3), 320–324 (2008).
  • Pece S , GutkindJS: Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell–cell contact formation.J. Biol. Chem.275(52), 41227–41233 (2000).
  • Black PC , BrownGA, InamotoTet al.: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.Clin. Cancer Res.14(5), 1478–1486 (2008).
  • Edwards SL , BroughR, LordCJet al.: Resistance to therapy caused by intragenic deletion in BRCA2.Nature451(7182), 1111–1115 (2008).
  • Sakai W , SwisherEM, KarlanBYet al.: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.Nature451(7182), 1116–1120 (2008).
  • Bellmunt J , AlbiolS, de OlanoAR, PujadasJ, MarotoP; on behalf the Spanish Oncology Genitourinary Group: Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.Ann. Oncol.17(Suppl. 5), V113–V117 (2006).
  • Olaussen KA , DunantA, FouretPet al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.N. Engl. J. Med.355(10), 983–991 (2006).
  • Ceppi P , VolanteM, NovelloSet al.: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.Ann. Oncol.17(12), 1818–1825 (2006).
  • Bellmunt J , Paz-AresL, CuelloMet al.: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.Ann. Oncol.18(3), 522–528 (2007).
  • Kim K , DoI, YiSet al.: ERCC1 expression in advanced bladder cancer patients receiving gemcitabine/cisplatin chemotherapy.Proc. Am. Soc. Clin. Oncol. (GU ASCO) (2009) (Abstract 269).
  • Taron M , RosellR, FelipEet al.: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.Hum. Mol. Genet.13(20), 2443–2449 (2004).
  • Quinn JE , JamesCR, StewartGEet al.: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.Clin. Cancer Res.13(24), 7413–7420 (2007).
  • Font A , TaronM, CostaCet al.: BRCA1mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy.Proc. Am. Soc. Clin. Oncol.26(15 Suppl.), 5021 (2008).
  • Lee JK , HavaleshkoDM, ChoHet al.: A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery.Proc. Natl Acad. Sci. USA104(32), 13086–13091 (2007).
  • Sharma P , ShenY, WenSet al.: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.Proc. Natl Acad. Sci. USA104(10), 3967–3972 (2007).
  • Zhang L , Conejo-GarciaJR, KatsarosDet al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N. Engl. J. Med.348(3), 203–213 (2003).
  • Naito Y , SaitoK, ShiibaKet al.: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.Cancer Res.58(16), 3491–3494 (1998).
  • Galon J , CostesA, Sanchez-CaboFet al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.Science313(5795), 1960–1964 (2006).
  • Nakano O , SatoM, NaitoYet al.: Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.Cancer Res.61(13), 5132–5136 (2001).
  • Danila DC , HellerG, GignacGAet al.: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.Clin. Cancer Res.13(23), 7053–7058 (2007).
  • Sastre J , MaestroML, PuenteJet al.: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.Ann. Oncol.19(5), 935–938 (2008).
  • Cristofanilli M , BuddGT, EllisMJet al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N. Engl. J. Med.351(8), 781–791 (2004).
  • Gallagher DJ , MilowskyMI, IshillNet al.: Detection of circulating tumor cells in patients with urothelial cancer.Ann. Oncol.20(2), 305–308 (2009).
  • Wu C , HaoH, LiLet al.: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.J. Thorac. Oncol.4(1), 30–36 (2009).
  • de Bono JS , ScherHI, MontgomeryRBet al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin. Cancer Res.14(19), 6302–6309 (2008).
  • Liew CC , MaJ, TangHC, ZhengR, DempseyAA: The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool.J. Lab. Clin. Med.147(3), 126–132 (2006).
  • Malats N , BustosA, NascimentoCMet al.: P53 as a prognostic marker for bladder cancer: a meta-analysis and review.Lancet Oncol.6(9), 678–686 (2005).
  • Choi NN , SonDSD-S, LeeJJet al.: The signature from messenger RNA expression profiling can predict lymph node metastasis with high accuracy for non-small cell lung cancer.J. Thorac. Oncol.1(7), 622–628 (2006).
  • Dressman HK , HansC, BildAet al.: Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.Clin. Cancer Res.12(3), 819–826 (2006).
  • Chen H-Y , YuS-L, ChenC-Het al.: A five-gene signature and clinical outcome in non-small-cell lung cancer.N. Engl. J. Med.356(1), 11–20 (2007).
  • Cronin M , SangliC, LiuMLet al.: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.Clin. Chem.53(6), 1084–1091 (2007).
  • Rouzier R , RajanR, WagnerPet al.: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.Proc. Natl Acad. Sci. USA102(23), 8315–8320 (2005).
  • Modlich O , PrisackH-B, PitschkeGet al.: Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.Clin. Cancer Res.10(10), 3410–3421 (2004).
  • Sanchez-Carbayo M , SocciND, LozanoJ, SaintF, Cordon-CardoC: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.J. Clin. Oncol.24(5), 778–789 (2006).
  • Dyrskjot L , ThykjaerT, KruhofferMet al.: Identifying distinct classes of bladder carcinoma using microarrays.Nat. Genet.33(1), 90–96 (2003).
  • Dyrskjot L , KruhofferM, ThykjaerTet al.: Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.Cancer Res.64(11), 4040–4048 (2004).
  • Elsamman E , FukumoriT, EwisAAet al.: Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results.Urol. Oncol.24(2), 109–115 (2006).
  • Sanchez-Carbayo M , SocciND, CharytonowiczEet al.: Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes.Cancer Res.62(23), 6973–6980 (2002).
  • Blaveri E , SimkoJP, KorkolaJEet al.: Bladder cancer outcome and subtype classification by gene expression.Clin. Cancer Res.11(11), 4044–4055 (2005).
  • Takata R , KatagiriT, KanehiraMet al.: Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.Clin. Cancer Res.11(7), 2625–2636 (2005).
  • Esquela-Kerscher A , SlackFJ: Oncomirs – microRNAs with a role in cancer.Nat. Rev. Cancer6(4), 259–269 (2006).
  • Hayashita Y , OsadaH, TatematsuYet al.: A polycistronic microRNA cluster, miR-17–92, is overexpressed in human lung cancers and enhances cell proliferation.Cancer Res.65(21), 9628–9632 (2005).
  • Si ML , ZhuS, WuH, LuZ, WuF, MoYY: miR-21-mediated tumor growth.Oncogene26(19), 2799–2803 (2007).
  • Chan JA , KrichevskyAM, KosikKS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.Cancer Res.65(14), 6029–6033 (2005).
  • Kent OA , MendellJT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.Oncogene25(46), 6188–6196 (2006).
  • Calin GA , CroceCM: MicroRNA signatures in human cancers.Nat. Rev. Cancer6(11), 857–866 (2006).
  • Tavazoie SF , AlarconC, OskarssonTet al.: Endogenous human microRNAs that suppress breast cancer metastasis.Nature451(7175), 147–152 (2008).
  • Yanaihara N , CaplenN, BowmanEet al.: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.Cancer Cell9(3), 189–198 (2006).
  • Lu J , GetzG, MiskaEAet al.: MicroRNA expression profiles classify human cancers.Nature435(7043), 834–838 (2005).
  • Iorio MV , FerracinM, LiuCGet al.: MicroRNA gene expression deregulation in human breast cancer.Cancer Res.65(16), 7065–7070 (2005).
  • Porkka KP , PfeifferMJ, WalteringKK, VessellaRL, TammelaTL, VisakorpiT: MicroRNA expression profiling in prostate cancer.Cancer Res.67(13), 6130–6135 (2007).
  • Volinia S , CalinGA, LiuCGet al.: A microRNA expression signature of human solid tumors defines cancer gene targets.Proc. Natl Acad. Sci. USA103(7), 2257–2261 (2006).
  • Bloomston M , FrankelWL, PetroccaFet al.: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.JAMA297(17), 1901–1908 (2007).
  • Neely LA , Rieger-ChristKM, NetoBSet al.: A microRNA expression ratio defining the invasive phenotype in bladder tumors.Urol. Oncol. (2009) (Epub ahead of print).
  • Sylvester RJ : Combining a molecular profile with a clinical and pathological profile: biostatistical considerations.Scand. J. Urol. Nephrol. Suppl. (218), 185–190 (2008).
  • Svatek RS , LotanY, KarakiewizcPI, ShariatSF: Screening for bladder cancer using urine-based tumor markers.Minerva Urol. Nefrol.60(4), 247–253 (2008).
  • Rosenblatt R , JonmarkerS, LewensohnRet al.: Current status of prognostic immunohistochemical markers for urothelial bladder cancer.Tumour Biol.29(5), 311–322 (2008).
  • van Tilborg AA , BangmaC, ZwarthoffEC: Bladder cancer biomarkers and their role in surveillance and screening.Int. J. Urol.16(1), 23–30 (2009).
  • Gu J , Barton GrossmanH, DinneyCP, WuX: The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence.Pharmacogenomics6(6), 575–584 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.